Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose sharply in today’s pre-market trading.
4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.
4D Molecular Therapeutics shares jumped 20.1% to $21.01 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
Losers
Now Read This: McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
